NICE has recommended teduglutide (Revestive) in final draft guidance for people with short bowel syndrome who are aged 1 year and above and are in a stable condition following surgery to remove an abnormal bowel.
Risankizumab shows meaningful improvement in symptoms compared to placebo in patients that were not responsive or intolerant to current available treatments, says the MHRA.
Avatrombopag is accepted for use within NHS Scotland for severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.